NCT07157969View on ClinicalTrials.gov

PD-1 Inhibitors Combined With Targeted Therapy With or Without Interventional Therapy for Advanced HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 30, 2027

Conditions
HCC - Hepatocellular Carcinoma
Interventions
DRUG

Lenvatinib

≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily

DRUG

Pembrolizumab

200 mg intravenously every three weeks

DRUG

Atezolizumab

1200 mg intravenously every three weeks

DRUG

Bevacizumab

15mg/kg intravenously every three weeks

DRUG

Camrelizumab

200 mg intravenously every three weeks

DRUG

Apatinib

250mg once daily

PROCEDURE

TACE

The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.

PROCEDURE

HAIC

The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.

PROCEDURE

DEB-TACE

The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER